The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II study of short CHOP-rituximab combination with early consolidation with ibritumomab-tiuxetan-Y90 (IT-Y90) in non-pretreated patients age 65 to 80 with CD20+ diffuse large B-cell lymphoma (DLBCL).
Frederic Peyrade
No relevant relationships to disclose
Gerard Lepeu
No relevant relationships to disclose
Jocelyn Gal
No relevant relationships to disclose
Christophe Fruchart
No relevant relationships to disclose
Diane Coso
No relevant relationships to disclose
Serge Bologna
No relevant relationships to disclose
Mariano Provencio
No relevant relationships to disclose
Regis Kaphan
No relevant relationships to disclose
Claudine Sohn
No relevant relationships to disclose
Bruno Audhuy
No relevant relationships to disclose
Gomez Codina
No relevant relationships to disclose
Antoine Thyss
No relevant relationships to disclose